Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Loop Capital Maintains Hold on Salesforce.com, Raises Price Target to $265

Loop Capital analyst Yun Kim maintains Salesforce.com (NYSE:CRM) with a Hold and raises the price target from $235 to $265.

byvishwanath@benzinga.com

August 27, 2021

1 minute read

Loop Capital analyst Yun Kim maintains Salesforce.com (NYSE:CRM) with a Hold and raises the price target from $235 to $265.

News
Tech

Snap To Offer Opportunities For Creators To Earn

By Anusuya Lahiri

Today, 9:57 AM

Snap Inc (NYSE:SNAP) announced Spotlight Challenges which will offer Snapchatters the chance to win cash prizes for creating top-performing Spotlight Snaps…

SNAP

Truist Securities Initiates Coverage On Instructure Holdings with Buy Rating, Announces Price Target of $26

By Benzinga Newsdesk

Today, 9:57 AM

Truist Securities analyst Terry Tillman initiates coverage on Instructure Holdings (NYSE:INST) with a Buy rating and announces Price Target of $26.

INST

Wolfe Research Downgrades Regal Rexnord to Peer Perform

By Benzinga Newsdesk

Today, 9:57 AM

Wolfe Research analyst Nigel Coe downgrades Regal Rexnord (NYSE:RRX) from Outperform to Peer Perform.

RRX

Legal
News

Minerva Neurosciences To Be Issued U.S. Patent Titled ‘GASTRO-RESISTANT CONTROLLED RELEASE ORAL DOSAGE FORMS (FOR THE TREATMENT OF SCHIZOPHRENIA)’

By Benzinga Newsdesk

Today, 9:57 AM

https://pbs.twimg.com/media/FaOLGwOUsAA-PAq.jpg

NERV

Loop Capital Maintains Hold on Salesforce.com, Raises Price Target to $265

Related Posts

Snap To Offer Opportunities For Creators To Earn

Truist Securities Initiates Coverage On Instructure Holdings with Buy Rating, Announces Price Target of $26

Wolfe Research Downgrades Regal Rexnord to Peer Perform

Minerva Neurosciences To Be Issued U.S. Patent Titled ‘GASTRO-RESISTANT CONTROLLED RELEASE ORAL DOSAGE FORMS (FOR THE TREATMENT OF SCHIZOPHRENIA)’